The Future of Motion is Here
Developed by Mayo Clinic’s Aerospace Medicine & Vestibular Research Laboratory, vMocion's Galvanic Vestibular Stimulation (GVS) technology enables profound new experiences.
Featuring Mayo Clinic’s patented GVS technology, vMocion’s 3v™ Platform creates a complete, three-dimensional sensation of motion while mitigating VR- and cyber- sickness in the vast majority of the population. Whereas, to prevent motion sickness without generating an added sense of motion, vMocion’s REMOVES™ technology safely suppresses the vestibular system.
Both technologies have a multitude of use cases across the VR/AR, film, television, gaming, mobile device, and amusement park ecosystems, in addition to many others. Without a sense of motion, a true sense of presence in a virtual world cannot exist.
vMocion™ is a motion technology company formed by Mayo Clinic and Hillstrom Media Technology to bring patented Galvanic Vestibular Stimulation (GVS) technology to the AR/VR, amusement park, and automotive markets, amongst many others. Together with strategic partners, vMocion develops end-user technology that alters the sense of motion to create a desired experience. Founded to revolutionize the sensory experience of motion, vMocion™ embraces the ideals of innovation at the intersection of biotechnology and emerging industry to alter the sense of motion and how it is desired or needed.
vMocion’s 3v™ Platform features Mayo Clinic’s patented GVS technology, which creates a complete, three-dimensional sensation of motion and mitigates VR sickness in the vast majority of the population. The technology and software is now available for licensing through vMocion and can be instantiated into everything from VR headsets and amusement park rides to self-driving cars and televisions.